Skip to content
Home/Companies/Biotech/Galecto

Galecto

Biotech·Denmark·Exited 2020·Held 8yr
Entry
2012
Hold
8yr
Exit
2020

Who owns Galecto?

Galecto is a Danish Biotech company, formerly owned by Sunstone Life Science Ventures, exited in 2020 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures III · 2007 · VC

Key facts

HQDenmark
SectorBiotech
StatusAcquired
Exit Type
IPO
Exit Year
2020

More from Sunstone Life Science Ventures III

Other portfolio companies in the same fund.

MinervaX
MinervaX
Active
BiotechDenmark· 2014
Cantargia
Exited 2015
BiotechSweden· 2013
Opsona Therapeutics
Exited 2019
BiotechIreland· 2013
Follicum
Exited 2014
BiotechSweden· 2012
to Swedish Growth Fund
Orphazyme
Orphazyme
Exited 2017
BiotechDenmark· 2011
to Eurazeo
Vaximm
Exited 2022
BiotechGermany· 2011
to NEC OncoImmunity

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Galecto?

Galecto was formerly owned by Sunstone Life Science Ventures, exited in 2020. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue